NCT06980740Recruiting
Video-Tumorboard PLUS
Source: ClinicalTrials.gov · Last updated 20 May 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
In weekly expert meetings for oncological diagnostics and therapy, known as tumor boards, individual therapy recommendations are developed for cancer patients. By further developing and optimizing the CCCs' video tumor boards, initially using skin cancer as an example, we want to ensure that more patients can benefit from the expertise of several specialist disciplines and innovations - regardless of where they live.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 16 Apr 2025
- Start date
- 1 May 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- University Hospital Muenster
- Diseases
- Melanoma
- NCT number
- NCT06980740
What you commit to
- Study type: Observational
- Planned participants: 300
- From 1 May 2025 to the primary completion date, 31 May 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Linguistic or other limitations (such as dementia) that prevent independent consent to the privacy policy.
Other
- Patients will be excluded from the study if they meet the following criteria:
- No consent to participate in the study (patient consent) or withdrawal of consent during the course of the study In addition, external physicians will be excluded from the study if no joint cooperation agreement can be negotiated and signed.
Who the study is looking for
- The study includes adult, external patients who, according to the certification requirements of the German Cancer Society, should be presented to the CCCs in a tumor board .
- Minimum age 18 years
- Consent to participate in the study (signing of patient consent) should be presented in vTB+ according to the doctor, based on the disease/diagnosis, especially in the case of:
- Malignant melanoma from stage IIB
- Malignant melanoma and stage shift/recurrence o Extracutaneous melanoma o Cutaneous lymphoma from stage Ib o Problem cases with malignant, epithelial tumors (BCC, SCC) with interdisciplinary issues, e.g. complicated localization, extension/ infiltration (e.g. Ulcus rodens, Ulcus terebrans), metastasized tumors, immunosuppressed patients o all rare malignant skin tumors (including Merkel cell carcinoma, DFSP, MFH, leiomyosarcoma, S., Kaposi's sarcoma, angiosarcoma), regardless of stage o severe side effects from drug-based tumor therapy • is an external patient: An external patient is someone who receives tumor therapy exclusively or in co-treatment in the branch or in an external clinic (in distinction to patients without prior treatment for initial presentation at the CCC) . This also applies to patients who are only seen once at the vTB.
- In this case, revenue/cost aspects and the DKG requirement are ignored. This means that so-called external patients can also be treated at the center, including initiation of therapy. The decisive factor is the presentation of the external patient (personal presentation of the external patients is not mandatory) and that external co-treaters are consistently informed and involved.
- has a medical license
- has dermatological patients who are eligible to be presented in the vTB+
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Abteilung für Integrierte Onkologie - CIO Bonn, Universitätsklinikum Bonn Coordinator of this site? Confirm its status | Bonn | Germany | Not yet recruiting |
| Nationales Centrum für Tumorerkrankungen Klinik u. Poliklinik für Dermatologie, Universitätsklinikum Dresden Coordinator of this site? Confirm its status | Dresden | Germany | Recruiting |
| Westdeutsches Tumorzentrum Münster, Universitätsklinikum Münster Coordinator of this site? Confirm its status | Münster | Germany | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.